Moreover, although both nivolumab and pembrolizumab are classified as anti-PD-1 antibodies, they appear to exhibit different thyroid toxicity profiles: nivolumab is more commonly associated with hypothyroidism, whereas pembrolizumab tends to be linked with a higher incidence of hyperthyroidism [30]. This evidence concerns the gene PDCD1 and hyperthyroidism.